Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile
Дата публикации: 06-10-2026 07:00:00

Findings from the PATHFINDER 2 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Mining fragmented microbial DNA identifies candidates for anticancer testing09.8401-10-2026
2FDA panel supports multicancer early detection test09.9724-09-2026
3ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence05.4301-09-2026
4Annual multicancer early detection test not associated with a lower incidence rate of stage III or IV cancer after three screening rounds and 12 months of follow-up017.3601-10-2026
5Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer015.0707-10-2026
6A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy010.9129-09-2026
7FDA panel endorses first-of-a-kind cancer blood test from Grail08.823-09-2026
8New study finds a blood test may detect recurring breast cancer faster than a scan08.631-08-2026
9Un simple análisis de sangre ‘barato’ detecta múltiples cánceres y enfermedades hepáticas en una prueba05.9507-04-2026
10FDA advisory panel recommends a first: multi-cancer blood test010.9123-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 18.7. Источник: www.esmo.org.